A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: From bench to bedside

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4801-4815

  Chiang, Cheryl Lai Lai ^a   Kandalaft, Lana E ^a   Tanyi, Janos ^a   Hagemann, Andrea R ^a   Motz, Gregory T ^a   Svoronos, Nikolaos ^a   Montone, Kathleen ^a   Mantia Smaldone, Gina M ^a   Smith, Lori ^a   Nisenbaum, Harvey L ^a   Levine, Bruce L ^a   Kalos, Michael ^a   Czerniecki, Brian J ^a   Torigian, Drew A ^a   Powell Jr , Daniel J ^a   Mick, Rosemarie ^b   Coukos, George ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CHEMOKINE; CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HYPOCHLOROUS ACID; INTERLEUKIN 10; INTERLEUKIN 12; OCDC VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ADVERSE DRUG REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CONTROL; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CELL FUNCTION; CELL LYSATE; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; INTERLEUKIN 10 BLOOD LEVEL; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; OVARY CANCER; OXIDATION; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECURRENT CANCER; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; TH1 CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOCHLOROUS ACID; IMMUNOTHERAPY; INTERLEUKIN-10; LYMPHOCYTE CULTURE TEST, MIXED; MICE; OVARIAN NEOPLASMS; OXIDATION-REDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84883466843     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1185     Document Type: Article

References (58)

1. Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T-cells. J Clin Oncol 2009;27:945-52.
2. Barth RJ Jr, Fisher DA, Wallace PK, Channon JY, Noelle RJ, Gui J, et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res 2010;16:5548-56.
3. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011;34:382-9.
4. Hernando JJ PT, Kübler K, Offergeld R, Schlebusch H, Bauknecht T. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51:45-52. (Pubitemid 34158522)
5. Kandalaft LE, Powell DJ Jr, Chiang CL-L, Tanyi J, Kim S, Bosch M, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo costimulated T-cells in recurrent ovarian cancer. Oncoimmunology 2013;2:e22664.
6. Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002;8:1021-32. (Pubitemid 35177351)
7. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJM, Jongmans W, Adema GJ, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002;25:500-8.
8. Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, et al. Dendritic cell immunotherapy for urological cancers using cryo-preserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 2004;94:412-8. (Pubitemid 39120190)
9. Neller MA, López JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol 2008;20:286-95.
10. Allison MED, Fearon DT. Enhanced immunogenicity of aldehyde-bearing antigens: a possible link between innate and adaptive immunity. Eur J Immunol 2000;30:2881-7.
11. Marcinkiewicz J, Chain BM, Olszowska E, Olszowski S, Zgliczynski JM. Enhancement of immunogenic properties of ovalbumin as a result of its chlorination. Int J Biochem 1991;23:1393-5.
12. Prokopowicz ZM, Arce F, Biedron R, Chiang CL-L, Ciszek M, Katz DR, et al. Hypochlorous acid: a natural adjuvant that facilitates antigen processing, cross-priming, and the induction of adaptive immunity. J Immunol 2010;184:824-35.
13. Chiang C, Ledermann J, Rad AN, Katz D, Chain B. Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T-cells. Cancer Immunol Immunother 2006;55:1384-95. (Pubitemid 44187670)
14. Chiang CL, Ledermann JA, Aitkens E, Benjamin E, Katz DR, Chain BM. Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T-cells that recognize autologous primary tumor. Clin Cancer Res 2008;14:4898-907.
15. Anderson MM, Hazen SL, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha, beta-unsaturated aldehydes by phagocytes at sites of in flammation. J Clin Invest 1997;99:424-32. (Pubitemid 27414799)
16. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nε-(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103-13. (Pubitemid 29534350)
17. Hazen SL, Hsu FF, Mueller DM, Crowley JR, Heinecke JW. Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest 1996;98:1283-9. (Pubitemid 26322052)
18. Carrasco-Marín E, Paz-Miguel J, López-Mato P, Alvarez-Domínguez C, Leyva-Cobián F. Oxidation of defined antigens allows protein unfolding and increases both proteolytic processing and exposes peptide epitopes which are recognized by specific T-cells. Immunology 1998;95:314-21. (Pubitemid 28505685)
19. Chiang C, Maier D, Kandalaft L, Brennan A, Lanitis E, Ye Q, et al. Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. J Transl Med 2011;9:198.
20. Chiang CL-L, Hagemann AR, Leskowitz R, Mick R, Garrabrant T, Czerniecki BJ, et al. Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS ONE 2011;6:e28732.
21. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988;54:777-85.
22. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998;72:8463-71. (Pubitemid 28471781)
23. Lee S, Tallman MS, Oken MM, Cassileth PA, Bennett JM, Wiernik PH, et al. Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Leukemia 2000;14:1345-8. (Pubitemid 30599313)
24. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004;22:3120-5. (Pubitemid 41103725)
25. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T-cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9. (Pubitemid 39273735)
26. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011;475:226-30.
27. Chu CS, Kim SH, June CH, Coukos G. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 2008;8:243-57. (Pubitemid 351385915)
28. Chiang CL-L, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010;22:132-43.
29. Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, et al. Tissue-based immune monitoring I: Tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. Cancer Biol Ther 2011;12:357-66.
30. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD, Freeman SM. Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 1997;28:321-31. (Pubitemid 27106085)
31. Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, et al. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. Br J Cancer 2011;105:1144-50.
32. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 2013;129:452-8.
33. Hattori E, Okumoto K, Adachi T, Takeda T, Ito J, Sugahara K, et al. Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatol Res 2003;27:309-14.
34. Chau G-Y, Wu C-W, Lui W-Y, Chang T-J, Kao H-L, Wu L-H, et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000;231:552-8. (Pubitemid 30185863)
35. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, et al. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 2004;10:7260-9. (Pubitemid 39487713)
36. Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev 2008;222:256-76. (Pubitemid 351430379)
37. Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ Jr. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 2001;61:641-6. (Pubitemid 32128627)
38. Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 2003;21:3826-35. (Pubitemid 46606238)
39. Gaekwad J, Zhang Y, Zhang W, Reeves J, Wolfert MA, Boons G-J. Differential induction of innate immune responses by synthetic lipid A derivatives. J Biol Chem 2010;285:29375-86.
40. Okemoto K, Kawasaki K, Hanada K, Miura M, Nishijima M. A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1β or activation of caspase-1. J Immunol 2006;176:1203-8. (Pubitemid 43099724)
41. ten Brinke A, Schijndel G, Visser R, Gruijl T, Zwaginga J, Ham SM. Monophosphoryl lipid A plus IFNγ maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T-cells with high cytolytic potential. Cancer Immunol Immunother 2010;59:1185-95.
42. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. J Clin Oncol 2011;29:330-6.
43. Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, et al. Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients. J Immunol 2011;187:6130-42.
44. Hardwick N, Ledermann J, Aitkens E, Chain B. Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease. Cancer Immuno Immunother 2012;61:1929-39.
45. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T-cell homing to tumors and disables immune therapy. Nat Med 2008;14:28-36.
46. Kandalaft LE, Motz GT, Busch J, Coukos G. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr Top Microbiol Immunol 2011;344:129-48.
47. Ghiringhelli F, Menard C, Puig P, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T-cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8. (Pubitemid 46348738)
48. Leao IC, Ganesan P, Armstrong TD, Jaffee EM. Effective depletion of regulatory T-cells allows the recruitment of mesothelin-specific CD8 T-cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clin Transl Sci 2008;1:228-39.
49. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009;27:5911-8.
50. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-17.
51. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-speci fic cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 1995;92:432-6.
52. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, et al. Identification of HLA-A2-restricted T-Cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309-17. (Pubitemid 29279274)
53. Chen J-L, Dunbar PR, Gileadi U, Jäger E, Gnjatic S, Nagata Y, et al. Identi fication of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000;165:948-55. (Pubitemid 30484763)
54. Gao L, Bellantuono I, Elsässer A, Marley SB, Gordon MY, Goldman JM, et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000;95:2198-203. (Pubitemid 30167714)
55. Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, et al. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 2005;11:6342-51. (Pubitemid 41262966)
56. Bernatchez C, Zhu K, Li Y, Andersson H, Ionnides C, Fernandez-Vina M, et al. Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. Vaccine 2011;29:3021-30.
57. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9. (Pubitemid 29302920)
58. Röpke M, Hald J, Guldberg P, Zeuthen J, Nørgaard L, Fugger L, et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A 1996;93:14704-7. (Pubitemid 26419032)